News

Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at hscora@ouhsc.edu so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, October 29, 2018

Questions about your VA appointment and externally funded research?  Forms, information,

and FAQs can be found here:

https://research.ouhsc.edu/Research-Administration/Policies/VA-Joint-Appointments

 

 

OUHSC will Celebrate Corporate Compliance and Ethics Week

Monday, November 5, 2018 through Friday, November 9, 2018.  There will be different activities related to

Compliance and Ethics each day.     Each day of Corporate Compliance and Ethics Week, you will receive

an email from Compliance to share news and ideas, and to announce the schedule of events for the day. 

Please see the attachment for more complete information.

https://research.ouhsc.edu/Portals/1329/Assets/Documents/Compliance and Ethics Week.pdf?ver=2018-10-22-073454-467

 

The Office of Technology Development will offer the Innovation to Impact Series Session 3

“Copyright, Trademark & Open Source.” The points to be discussed: Not all intellectual property is

patentable; Filing for copyrights and trademarks, Protecting your software application and Examples

of licensing non-traditional IP.

This session will occur on October 31st  from Noon- 1:00 pm in Biomedical Research Center Building,  

Room 103. Lunch will be provided.   Please RSVP to rashaffer@ou.edu by October 26th. Space is

limited to the first 15 attendees.

 

 

2019 Annual Cancer Research Symposium | Registration & Call for Abstracts

Abstracts due Friday, November 16, 2018.  Conference is Friday, February 1, 2019. 

See attached document for additional information.

https://research.ouhsc.edu/Portals/1329/Assets/Documents/Cancer Research Symposium.docx?ver=2018-10-08-074829-697

 

ORAU-Directed Research and Development (ODRD) Program

The FY 2019 competition for collaborative awards of up to $75,000 to be shared between the university

and ORAU researchers is now open. We anticipate and expect that these seed funds will position the

collaborative teams to be more competitive for new, external funding opportunities. The deadline for

joint ORAU/university proposals is March 25, 2019 and potential university partners are encouraged

to submit concepts for discussion with ORAU partners as soon as possible. 

https://www.orau.org/university-partnerships/member-grant-programs/odrd.html

 

 

PHF Bridge Grant PROGRAM

Proposal Deadline: Friday, November 16, 2018

The primary objective of the PHF Bridge Grant program is to provide funding of limited duration to

enhance OUHSC faculty competitiveness for NIH R01 and Department of Defense (DoD) extramural

funding.  PHF Bridge Grant funding is specifically for those OUHSC faculty members who have

submitted R01 applications to NIH or applications to DoD that have been reviewed and scored,

but not funded.   Applicants may request support of up to $75,000 for one year.

Guidelines and Application Form is attached or go to:

https://research.ouhsc.edu/News/TabId/9629/ArtMID/25795/ArticleID/8107/PHF-Bridge-Grant-Program-Fall-2018.aspx.

https://research.ouhsc.edu/Portals/1329/Assets/Documents/PHF-Bridge Grant-Guidelines - Final - November 2018.docx?ver=2018-10-08-074830-023

 

END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer

Conference

Dates: December 6-7, 2018

Location: Samis Education Center

Registration and Call for Abstracts: http://end2cancer.com/

Summary: The END2CANCER conference will start the morning of December 6th, 2018 and conclude

in the afternoon of December 7th, 2018. The conference will bridge laboratory research conducted in

the areas of nanotechnology and drug delivery to clinical application for the detection, diagnosis,

imaging and treatment of cancer. The conference will host keynote, plenary and invited lectures by

eminent scientists who will discuss new and emerging concepts, technologies and challenges in

translating nanomedicine from bench-to-bedside.

Topics to be discussed in the planned thematic sessions include barriers in drug delivery, discovery

and applications, biological and non-biological systems as carriers and therapeutics, molecular imaging,

biomimetics, immune-oncology, toxicology and clinical trials.

The multi-disciplinary two-day conference will bring together physicians, basic scientists, engineers,

physicists, chemists, post-doctoral fellows, high-school and college students, patient advocates, business

professionals, educators and technology transfer specialists. Students and fellows will have an opportunity

to present their work as a poster presentation and compete for awards.

https://research.ouhsc.edu/Portals/1329/Assets/Documents/End2Cancer.docx?ver=2018-08-20-072712-953

 

NIH NOTICES

 

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to NIH SBIR

Omnibus Solicitations (NOT-OD-19-019)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-019.html

 

Responsibilities of Recipient Institutions in Communicating Research Misconduct to the NIH

(NOT-OD-19-020)
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-020.html

 

Notice to allow SBIR Direct-to-Phase II Application Type for NIAAA-issued Funding Opportunity

Announcement PAR-18-786, "Wearable Alcohol Biosensors (SBIR) (R43/R44- Clinical Trial Optional)"

(NOT-AA-18-011)
https://grants.nih.gov/grants/guide/notice-files/NOT-AA-18-011.html

 

Notice of Webinar and FAQs for NIAID Vaccine and Treatment Evaluation Units (UM1 Clinical Trial

Required) and Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC)

(UM1 Clinical Trial Required), RFA-AI-18-046 and RFA-AI-18-047 (NOT-AI-19-008)
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-19-008.html

 

Request for Proposal (RFP): Bioinformatics Resource Center for Infectious Diseases,

RFP-NIAID-DMD-NIHAI1201800005 (NOT-AI-19-009)

https://grants.nih.gov/grants/guide/notice-files/NOT-AI-19-009.html

 

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to PAR-18-303

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care

(R43/R44 Clinical Trial Not Allowed) (NOT-CA-19-002)
https://grants.nih.gov/grants/guide/notice-files/NOT-CA-19-002.html

 

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to PAR-18-801

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings

(R43/R44 - Clinical Trial Optional) (NOT-CA-19-003)
https://grants.nih.gov/grants/guide/notice-files/NOT-CA-19-003.html

 

Expert Panel Meeting to Discuss Study Design for a Longitudinal Study of the Impact of Prenatal

Opioid and Other Substance Exposure on Brain and Behavioral Development (NOT-DA-18-047)
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-18-047.html

 

Notice of Correction to Application Types Allowed" in PAR-18-522 NEI Collaborative Clinical Vision

Project: Resource Center Grant (UG1- Clinical Trial Required) (NOT-EY-19-001)
https://grants.nih.gov/grants/guide/notice-files/NOT-EY-19-001.html

 

Notice of Correction to Application Types Allowed" in PAR-18-523 NEI Collaborative Clinical Vision

Research Project : Chair's Grant (UG1-Clinical Trial Required) (NOT-EY-19-002)
https://grants.nih.gov/grants/guide/notice-files/NOT-EY-19-002.html

 

Notice of Correction to Application Types Allowed" in PAR-18-521 NEI Collaborative Clinical Vision

Research Project: Coordinating Center Grant (UG1- Clinical Trial Required) (NOT-EY-19-003)
https://grants.nih.gov/grants/guide/notice-files/NOT-EY-19-003.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for the Development, Implementation,

and Management of a Funding System to support the Grade A Milk Safety Program and National

Shellfish Sanitation Program (NOT-FD-19-001)
https://grants.nih.gov/grants/guide/notice-files/NOT-FD-19-001.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Research on Sleep and

Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to

Medication Assisted Treatment (MAT) - (U01 Clinical Trial Optional) (NOT-HL-18-655)
https://grants.nih.gov/grants/guide/notice-files/NOT-HL-18-655.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for Basic Research on Sleep and

Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to

Medication Assisted Treatment (MAT) (R01 - Clinical Trial Not Allowed) (NOT-HL-18-656)
https://grants.nih.gov/grants/guide/notice-files/NOT-HL-18-656.html

 

Request for Information (RFI) on the Proposed Funding Priorities for Neuroscience Research, Input

on Cross-Cutting Opportunities (NIH Neuroscience Blueprint) (NOT-NS-19-002)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-002.html

 

Notice of Clarification: Research Strategy page limit for RFA-NS-18-046 Analytical and/or Clinical

Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional) (NOT-NS-19-004)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-004.html

 

Notice of Clarification: Research Strategy page limit for PAR-18-548, Clinical Validation of a

Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional) (NOT-NS-19-005)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-005.html

 

Notice of Clarification: Research Strategy page limit for PAR-18-664, Clinical Validation of a

Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional) (NOT-NS-19-006)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-006.html

 

Notice of Clarification: Research Strategy page limit for PAR-18-550, Analytical Validation of a

Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional) (NOT-NS-19-007)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-007.html

 

Notice of Clarification: Research Strategy page limit for PAR-18-549, Analytical Validation of a

Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional) (NOT-NS-19-008)
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-008.html

 

Notice of Availability of Administrative Supplements for Microphysiological Systems Developers :

Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose (NOT-TR-19-001)
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-001.html

 

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to NCATS Platform

Delivery Technologies for Nucleic Acid Therapeutics (R43/R44) Funding Opportunity Announcement

(NOT-TR-19-004)
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-004.html

 

Notice of Intent to Publish a Funding Opportunity Announcement to Support Biofabricated 3D Tissue

Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical

Trial Not Allowed) (NOT-TR-19-006)
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-006.html

 

Notice of Intent to Publish a Funding Opportunity Announcement for Tissue Chips to Model Nociception,

Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed) (NOT-TR-19-007)
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-007.html

 

 

Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least one month prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.

 

NIH DEADLINES

 

Lymphatics in Health and Disease in the Digestive System (R01 Clinical Trial Not Allowed)

(RFA-DK-18-021) - Deadline February 21, 2019
https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-021.html

 

BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain

Science (R01 Clinical Trial Optional) (RFA-MH-19-400) – Deadline February 4, 2019
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-400.html

 

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp

Clinical Trial Not Allowed) (PA-19-029) – Deadline November 19, 2018 and January 28, 2019
https://grants.nih.gov/grants/guide/pa-files/PA-19-029.html

 

Administrative Supplements for Complementary Health Practitioner Research Experience (Admin

Supp Clinical Trial Optional) (PA-19-031) – Deadline April 1, 2019
https://grants.nih.gov/grants/guide/pa-files/PA-19-031.html

 

Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed) (PAR-19-027)

Deadline February 4, 2019
https://grants.nih.gov/grants/guide/pa-files/PAR-19-027.html

 

Basic Neurodevelopmental Biology of Brain Circuits and Behavior (R21 Clinical Trial Not Allowed)

(PAR-19-028) – Deadline February 4, 2019
https://grants.nih.gov/grants/guide/pa-files/PAR-19-028.html

 

NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) (PAR-19-030)

Deadline January 25, 2019
https://grants.nih.gov/grants/guide/pa-files/PAR-19-030.html

Print

x